There is very recent evidence of a patient doing well on Chugai for several months and just developed a number of brain mets.
It may very well be that Chugai is unable to deal with brain mets, and if that is the actual case, then 113 may very well be differentiated from the drug that just was fast tracked.
Perhaps we will get some clarifying data this weekend at ESMO,
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.